Revance Therapeutics, Inc. (RVNC) stock experienced sudden downfall – Reasons behind it!
Revance Therapeutics, Inc. (RVNC) has experienced a decline of 33.07% in the aftermarket because the company provided a Regulatory Update on DaxibotulinumtoxinA. However, the last trading session concluded at $22.71 with an increase of 0.66%. Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines On 15th October 2021, […]